

CURRICULUM VITAE

James P. Thomas MD, PhD

**Professor
Department of Medicine
Division of Hematology and Oncology - Medicine**

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:

1978 - 1982 BS, Zoology/History, University of Wisconsin-Madison, Madison, WI
1983 - 1985 University of Wisconsin Medical School, Madison, WI
1985 - 1989 PhD, Medical College of Wisconsin, Milwaukee, WI
1988 - 1991 MD, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1991 - 1995 Internal Medicine Residency, Clinical Investigator Track, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
1991 - 1995 Postdoctoral Research Fellow, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI
1991 - 1995 Adjunct Instructor, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI
1995 - 1998 Medical Oncology Fellow, University of Wisconsin Comprehensive Cancer Center, Madison, WI
1997 - 1998 Research Associate, Physician Scientist Training Award, Department of Human Oncology, University of Wisconsin Medical School, Madison, WI

FACULTY APPOINTMENTS:

1998 - 1999 Clinical Instructor, Department of Medicine, Section of Medical Oncology, University of Wisconsin Medical School, Madison, WI
1999 - 2005 Assistant Professor, Department of Medicine, Section of Medical Oncology, University of Wisconsin Medical School, Madison, WI
2005 - 2010 Associate Professor, Department of Medicine, Division of Hematology/Oncology, The Ohio State University, Columbus, OH
2005 - 2010 Medical Director, Clinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2010 - Present Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2010 - Present Associate Director, Clinical Investigation, Medical College of Wisconsin Cancer Center, Milwaukee, WI
2010 - Present Secondary Appointment, Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI
2010 - Present Medical Director, Clinical Trials Office, Medical College of Wisconsin Cancer Center, Milwaukee
2010 - Present Section Head, Solid Tumor Oncology, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2014 - Present Professor, Graduate School of Biomedical Sciences, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
A.B.I.M./Internal Medicine Board Certification	1997	2007
A.B.I.M./Subspecialty Board of Medical Oncology	1999	2020

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Wisconsin License	35184	1994	2005
Illinois State License	36097630	1998	2008
Ohio State License Registration	35-087459	2006	2011
Wisconsin License	35184	2010	2017

AWARDS AND HONORS:

1983 Outstanding Student Award, M-1, University of Wisconsin
1985 American Heart Predoctoral Fellowship
1986 Student Travel Awards, American Society for Photobiology
1988 Outstanding Young Investigator Award, Oxygen Society
1988 Student Travel Awards, American Society for Photobiology
1989 Medical College of Wisconsin: Outstanding Dissertation Award
1991 Armand J. Quick Award in Biochemistry
1993 Physician Scientist Training Grant Awardee
1995 Internal Medicine Seminar Award
2009 Wisconsin Small Business Innovation Award, Percitus Biosciences
2014 Grassroots Champion for Patient Access Award, Association of Community Cancer Centers
2015 Voted Best Doctor, Medical Oncology and Hematology, M Magazine Milwaukee

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1988 - Present Society for Free Radical Biology & Medicine (Formerly The Oxygen Society)
1996 - Present ASCO- American Society for Clinical Oncology.
1996 - Present AACR- American Association for Cancer Research.
2005 - Present CALGB- Cancer and Leukemia Group B.
2006 - Present NCCN- National Comprehensive Cancer Network Colon Cancer Panel
2007 - Present ISGIO- International Society of Gastrointestinal Oncology
2008 - 2012 AACI, CRI- American Association of American Cancer Institutes Clinical Research Initiative (Chair)
2009 - Present Theradex NIH Medical Branch (External Auditor)
2010 - Present Wisconsin Oncology Network
2010 - 2011 Pharmacy, Therapeutics, and Drug Utilization Committee

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorial Board
2001 Colorectal Cancer Index and Reviews
Journal Review
Archives of Biochemistry and Biophysics
Free Radicals in Biology and Medicine
Journal of the National Comprehensive Cancer
Annals of Surgery
Lancet
Cancer Chemotherapy & Pharmacology
Journal of Clinical Oncology
Journal of Biological Chemistry
Oncology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1998 - 2005 Member, Developmental Therapeutics Program (Phase I), UWCCC
 1998 - 2005 Leader, Gastrointestinal Oncology Disease Working Group, UWCCC
 1998 - 2005 Faculty Advisor, Pharmaceutical Research Center, UWCCC
 1998 - 2005 Member, Chemoprevention Program, UWCCC
 1998 - 2005 Chair, Investigator Initiated Trials Committee, UWCCC
 1998 - 2005 Member, Gastrointestinal Oncology Research Group, UWCCC
 1998 - 2005 Grand Rounds Coordinator, Gastrointestinal Oncology, UWCCC
 2002 - 2005 Chairman, Pharmaceutical Research Center, "Bowlin for Colons" Annual Fundraising Event, Madison, UWCCC
 2005 - 2010 Member, Experimental Therapeutics Program, OSUCCC
 2005 - 2010 Medical Director, Clinical Trials Office, OSUCCC
 2005 - 2010 Member, GI Cancers Disease Committee, OSUMC
 2006 - 2010 Chair, Data Safety Monitoring Committee, OSUCCC
 2006 - 2010 Member, Clinical Science Review Executive Committee, OSUCCC
 2006 - 2010 Co-Chair, Clinical Research Link Steering Committee, OSUCCC
 2006 - 2010 Member, Phase II Advisory Committee, OSUMC
 2008 - 2010 Member, Pharmaceuticals and Therapeutics Executive Committee, OSUMC
 2008 - 2010 Member, Project One Building Committee: Research & Education, OSU
 2008 - 2010 Member, CTSA steering Committee, OSUMC
 2009 - 2010 Co-Chair, Cancer Clinical Trial Feasibility Review Committee, Ohio State University (OSU)
 2009 - 2010 OSU Co-Chair, Ohio Cancer Consortium Executive Committee, Ohio State University, Case-Western, & Cleveland Clinic
 2009 - 2010 Member, Clinical Advisory Panel for the Colorectal Oncology Project, Institute for Pharmacy Outcomes of the Rx Ohio Collaborative
 2010 - 2011 Member, Clinical Trials Office Implementation Committee, Medical College of Wisconsin Cancer Center
 2011 - 2013 Member, Joan A. Van Deuren Breast Cancer Search Committee, Medical College of Wisconsin
 2012 - Present Member, Liver/Pancreas Symposium Planning Committee, Medical College of Wisconsin
 2012 - Present Member, National Clinical Trial Lead Agency Application U10 Cancer Cooperative Group Executive Committee, Medical College of Wisconsin
 2012 - 2013 Member, National Center for Systems Biology Search Committee, Medical College of Wisconsin
 2012 - Present Member, Clinical Research Optimization Committee, Medical College of Wisconsin
 2012 - 2013 Member, Department of Human Resources Talent Development Vendor Committee, Medical College of Wisconsin
 2012 - Present Medical Director, Translational Research Unit, Medical College of Wisconsin Cancer Center
 2013 - Present Member, American Cancer Society Pilot Research Grant Committee, Medical College of Wisconsin Cancer Center
 2013 - Present Co-Director, Updates in Gastrointestinal Oncology Symposium Planning Committee, Medical College of Wisconsin
 2014 - Present Member, Basic Science Seed Grant Review Committee, Medical College of Wisconsin Cancer Center

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

09/2002 Member, Progress Review Group, National Cancer Institute
 2002 - 2004 Member, Annual Meeting Program Committee, American Society for Clinical Oncology
 2004 Reviewer, Drug Discovery Groups for Cancer Solicitation, National Cancer Institute
 2006 - 2011 Member, Colon Cancer Panel, National Comprehensive Cancer Network
 06/12/2008 - 06/13/2008 Member, Research Advisory Council, EPIC, Madison, WI
 2008 - 2012 Chair, Clinical Research Initiative, Association of American Cancer Institutes
 2010 Member, Clinical Trials Reporting Program Strategic Subcommittee, National Cancer Institute
 2011 - 2013 Reviewer, Small Business Innovation and Research Program and Review, National Cancer Institute
 2012 - Present Member, Clinical Research Initiative Executive Committee, Association of American Cancer Institutes
 Consultant, Onyx
 Consultant, Sirtex
 Consultant, Sanofi-Synthelabo

Consultant, Precision Therapeutics
Consultant, Novartis Pharmaceuticals
Consultant, Genentech
Consultant, Eli Lilly Pharmaceuticals
Consultant, Amgen
Consultant, Pfizer

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	Cancer Center Infrastructure Grant, Funding Proposal ID: FP00001365
Source:	Advancing a Healthier Wisconsin
Role & Effort:	Associate Director (Funded at 20% Effort National Institutes of Health Cap)
PI:	Ming You
Dates:	11/01/2010 - 10/31/2016
Direct Funds:	\$3,756,568
Title:	Cancer Center Clinical Trials Office
Source:	Kurtis R. Froedtert Trust
Role & Effort:	Principal Investigator (Medical Director, Clinical Trials Office); (Funded at 14% Effort National Institutes of Health Cap)
Dates:	2011 - 2016
Direct Funds:	\$3,000,000
Title:	Nitric Oxide Mediated Modulation of Cancer Cell Metabolism, Funding Proposal ID: FP00004270
Source:	Medical College of Wisconsin Cancer Center
Role & Effort:	Co-Principal Investigator
PI:	Neil Hogg
Dates:	07/01/2012 - 06/30/2013
Direct Funds:	\$40,000

Pending

Peer Review

Title:	National Cancer Institute, National Cancer Trials Network, Funding Proposal ID: FP00004664
Source:	National Cancer Institute (U10)
Role & Effort:	Principal Investigator (Multiple PI application; Submitted at 7% Effort National Institutes of Health Cap)
PI:	Elizabeth Gore (lead), James Thomas, Stuart Wong, Janet Radar, David Johnstone
Direct Funds:	\$4,356,827
Title:	Preclinical Development of a Novel Chemoprotectant
Source:	Small Business Innovation Research Award , National Cancer Institute (R43)

Role & Effort:	Principal Investigator
Direct Funds:	\$1,200,000
Title:	Nitric Oxide Synthase 2 in Breast Cancer Metabolism, Funding Proposal, Funding Proposal ID: FP00003892a
Source:	National Cancer Institute (K99)
Role & Effort:	Co-Principal Investigator
PI:	Balaraman Kalyanaraman
Direct Funds:	\$707,295
Title:	Integrated Cancer Research Education Program, Funding Proposal ID: FP00003851
Source:	National Cancer Institute (R25)
Role & Effort:	Co-Principal Investigator
PI:	Carol Williams
Direct Funds:	\$774,243

Prior

Peer Review

Title:	Cancer and Leukemia Group B (CALGB), Grant #: 5 U10 CA077658-11
Source:	National Cancer Institute
Role & Effort:	Collaborator (Funded at 5% Effort National Institutes of Health (NIH) Cap)
PI:	Clara Bloomfield
Dates:	04/16/1998 - 03/31/2009
Direct Funds:	\$300,345
Title:	Early Therapeutics Development with Phase II Emphasis, Grant N01 CM17104
Source:	National Cancer Institute
Role & Effort:	Co-Principal Investigator and Site PI
PI:	Charles Erlichman
Dates:	02/01/2001 - 04/25/2005
Direct Funds:	\$62,088
Title:	Early Clinical Trials of New Anticancer Agents with Phase I Emphasis, Grant #: 2U01 CA62491-10
Source:	National Cancer Institute
Role & Effort:	Co-Principal Investigator
PI:	George Wilding
Dates:	03/01/2003 - 01/31/2008
Direct Funds:	\$367,577
Title:	Phase I Trials of Anti-Cancer Agents, Grant #: 2 U01 CA76576-11
Source:	National Cancer Institute
Role & Effort:	Co-Investigator (Funded at 5% Effort National Institutes of Health (NIH) Cap)
PI:	Michael Grever
Dates:	03/15/2003 - 2010
Direct Funds:	\$483,618

Title: Cancer Center Support Grant, Grant #:
P30 CA014520-32
Source: National Cancer Institute
Role & Effort: Faculty Leader Pharmaceutical Research
Center
PI: George Wilding
Dates: 04/01/2004 - 03/31/2006
Direct Funds: \$3,617,900

Title: Ischemia-Reperfusion with Neovascular
Toxins, Grant #: IRG-58-011-47-12
Source: American Cancer Society (Institutional
Research Grant)
Role & Effort: Principal Investigator
Dates: 04/26/2004 - 04/25/2005
Direct Funds: \$10,000

Title: The Ohio State University
Comprehensive Cancer Center Support
Grant, Grant #: 5 P30 CA016058-33
Source: National Cancer Institute
Role & Effort: Co-Investigator (Funded at 5% Effort
National Institutes of Health (NIH) Cap)
PI: Michael Caligiuri
Dates: 12/01/2004 - 11/30/2009
Direct Funds: \$2,530,349

Title: Phase II Randomized Trial of
Sequentially Administered CPT-11 and
Mitomycin C in Patients with Advanced
Esophageal and Stomach Cancer
Source: National Cancer Institute
Role & Effort: Co-Principal Investigator and Site PI
PI: Miguel Villalona
Dates: 2004 - 2007
Direct Funds: \$50,000

Title: Small Business Innovation Research
Award "Singlet Oxygen-Mediated
Protein Proximity Assay"
1R43CA134465-01
Source: National Cancer Institute
Role & Effort: CEO, Founder, Percitus Biosciences
Dates: 07/01/2008 - 06/31/2009
Direct Funds: \$110,000

Title: Small Business Innovation Research
Award "A Novel Compound to
Selectively Protect Normal Tissues for
Chemotherapy" 1R43CA137933-01A2
Source: National Cancer Institute
Role & Effort: CEO, Founder, Percitus Biosciences
Dates: 09/01/2009 - 08/31/2010
Direct Funds: \$147,830

Title: Nitric Oxide Mediated Modulation of
Cancer Cell Metabolism, Funding

Source:	Proposal ID: FP00001820 Medical College of Wisconsin Cancer Center
Role & Effort:	Co-Principal Investigator
PI:	Neil Hogg
Dates:	07/01/2011 - 06/30/2012
Direct Funds:	\$50,000
Title:	Phase II Trial of Perillyl Alcohol in Colorectal Cancer, Grant: R03 CA73906-01
Source:	National Cancer Institute
Role & Effort:	Co-Principal Investigator
PI:	Jordan Berlin
Direct Funds:	\$100,000
Title:	Translational Research Initiative SAHA Trials, Grant: 3 P30 CA014520 38S
Source:	National Cancer Institute
Role & Effort:	Author and Principal Investigator (TRI Subcontract 24XS097)
PI:	George Wilding (U01)
Direct Funds:	\$160,000
Title:	Phase I Clinical Trial of Flavopiridol
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC#615348) Plus Fluorouracil/Leucovorin (5-FU/LV) versus Fluorouracil/Leucovorin Alone after Curative Resection for Patients with Stage III Colon Cancer
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	A Phase I and Pharmacokinetic Trial of AR-12
Source:	ARNO Scientific
Role & Effort:	Protocol Chair
Title:	Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients with Advanced Solid Tumors and B-cell Lymphoproliferative Disorders
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	Translational Research Initiative Erlotinib Avastin Trial, Grant: 3 P30 CA014520 38S
Source:	National Cancer Institute
Role & Effort:	Principal Investigator (TRI Subcontract)

PI:	George Wilding (U01)
Direct Funds:	\$160,000
Title:	NCI Translational Research Initiative Triapine Trials, Grant: 3 P30 CA014520 38S
Source:	National Cancer Institute
Role & Effort:	Principal Investigator (TRI Subcontract 24XS090)
PI:	George Wilding
Direct Funds:	\$284,000
Title:	Phase I Study of Eniluracil, Oral 5-FU and Gemcitabine in Patient with Advanced Malignancy
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	Phase I and Pharmacodynamic Study of Proteasome Inhibitor, PS_341, in Combination with Doxorubicin in Patients with Advanced Solid Tumors
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	Phase I Study of Endostatin in Patients with Advanced Cancer
Source:	Cancer Therapy Evaluation Program (CTEP)/National Cancer Institute (NCI)
Role & Effort:	Protocol Chair
Title:	Chemoprevention of Skin Cancer: Difluoromethylornithine (DFMO) Phase III Trial, Grant: U01 CA77158-05
Source:	National Cancer Institute
Role & Effort:	Co-Principal Investigator
PI:	Howard Bailey
Direct Funds:	\$340,232

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

"The Emerging Role of Reactive Oxygen Species in Cancer Therapy", RTOG Symposium, Montreal, Canada, 2003

"CTO, CRO, and international trials", Delegation to visit Taiwan, 2006

"CTO, CRO, and international trials", Delegation to visit Taiwan, 06/18/2008 - 06/25/2008

Tumor Board: Metastatic disease, World Conference of Interventional Oncology, New York, NY, 05/18/2013

"How Locoregional Therapies Can Maximize the Therapeutic Effects of Chemotherapy", World Conference of Interventional Oncology, New York, NY, 05/18/2013

National

"New Advances in Chemotherapy", Amgen Annual Meeting, 1996

"A Phase I Trial of Gemcitabine Taxol and Piritrexim", Lilly Gemcitabine Investigators Meeting, 1997

"Recent Developments with Antiangiogenesis Agents", Third Annual Cancer Symposium, Resurrection Health Care System, 1999

"Angiogenesis in Renal Cell Cancer", First International Kidney Cancer Symposium, 1999

"Clinical Developments with Angiogenesis Inhibitors", Imaging and Radiation Sciences Colloquium, 2000

"Advances in the Treatment of Colorectal Cancer", Kettering Cancer Center Tumor Board, 2000

"Endostatin Phase I", Cancer Therapy Evaluation Program (CTEP) Drug Development Meeting, 2000

"Phase I Trial of Endostatin", Cancer and Leukemia Group B Semiannual Meeting, 2000

"Correlative Studies for Early Human Trials of Angiogenesis Inhibitors", National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Drug Development Phase I Meeting, 2000

"Update in Gastrointestinal Cancers", St. Vincent Hospital CME Oncology Series, 2001

"Gastrointestinal Oncology: Millennial Update", Gunderson Lutheran Grand Rounds, 2001

"New Drug Development", Northwestern University American Society for Clinical Oncology Review, 2001

"Angiogenesis Inhibitors as Anticancer Agents", Share the Knowledge Breast Cancer Symposium, 2001

"Future Trends in Redox Manipulation in Chemotherapy and Radiation Therapy", ASTRO Satellite Symposium, San Francisco, CA, 2001

"The Ubiquitin-Proteasome System in Anticancer Therapy", Cancer Pharmacology Seminar Series, 2001

"Recent Advances in the Treatment of Colon Cancer", University of Alabama Cancer Center Grand Rounds, 2001

"Angiogenesis Inhibitors as Anticancer Agents", University of Alabama Cancer Center Symposium, 2001

"Angiogenesis Inhibitors", Bascom Hill Society, 2001

"New approaches to Colorectal Cancer", University of Iowa Cancer Center Grand Rounds, 2002

"New Approaches to Treatment for Colorectal Cancer", 13th Annual Oncology Conference, Munson Medical Center, 2002

"The Ongoing Challenge of Pancreatic Cancer", 13th Annual Oncology Conference, Munson Medical Center, 2002

Discussant, American Society for Clinical Oncology Annual Meeting, Orlando, FL, 2002

"Clinical Trials with Recombinant Human Endostatin in Cancer Patients", Mayo Clinic Cancer Center Colloquium Series, 2002

"A Phase I Trial of PS-341 and Doxorubicin", NCI Spring Phase I Symposium, 2002

Cancer Residency for Clergy and Pastoral Ministries, 2003

Session Chair, American Society for Clinical Oncology Annual Meeting, Chicago, IL, 2003

"Phase I Trial of PS341 and Doxorubicin", Cancer Therapy Evaluation Program (CTEP)/Phase I meeting, 2004

Discussant, American Society for Clinical Oncology Annual Meeting, New Orleans, LA, 2004

Gastrointestinal Cancers Update from ASCO GI Symposium, 2006

LIMBWOOG Symposium on Treatment of Metastatic Liver Cancers, Ohio State University James Cancer Hospital & Solove Research Institute, 2006

"Developmental Chemotherapy", From Abstract to Bedside - Current Practice Recommendations as Influenced by the 2006 ASCO Annual Meeting, 2006

"Colorectal GI Cancer Advances in Treatment", Colon Cancer Alliance, Columbus, OH, 05/05/2007

"Targeting VEGF in Metastatic Colorectal Cancer: An Overview of Avastin (bevacizumab)", Columbus, OH, 05/22/2007

"Current Updates on State of the Art Screening, Prevention, and Multi-Disciplinary Treatment", Gastrointestinal Cancers 2007, Columbus, OH, 10/27/2007

"Colon Cancer: Adjuvant Therapy", Oncology Review 2008, Review and Interpretation of the 2008 ASCO and AACR Meetings, Current updates on the state of the art management of oncologic and hematologic diseases, Columbus, OH, 06/21/2008

Panel Member, National Comprehensive Cancer Network Colon Cancer Panel Meeting, Philadelphia, PA, 07/29/2008

"Colon Cancer Adjuvant Interactive Case Study: Community vs. Academic Perspectives", 2008 Gastrointestinal Cancer Symposium, Columbus, OH, 10/04/2008

Co-Chair, American Association for Cancer Research Small Molecule Therapeutics Agents Section Program Committee, 2009 American Association for Cancer Research Program Committee Meeting, Philadelphia, PA, 01/16/2009 - 01/17/2009

Chair, Association of American Cancer Institutes Clinical Research Working Group Steering Committee Meeting, Pittsburgh, PA, 01/29/2009 - 02/29/2009

"Histones, Tubulins, and Proteasome Targets." (Minisymposium), The 100th AACR Annual Meeting, Denver, CO, 04/22/2009

"Current and emerging therapies for HCC", 2009 Update in the Evaluation and Management of

Hepatocellular Cancer Meeting, Columbus, OH, 04/25/2009

"Treatment of Metastatic Colon Cancer", 2009 ASCO Review Meeting, Columbus, OH, 06/20/2009

"AACI CRI Overview and Proposed Activities", Clinical Research Initiative (CRI) Meeting, Chicago, IL, 07/16/2009

Panel Member, National Comprehensive Cancer Network Colon Cancer Panel Meeting, Philadelphia, PA, 07/21/2009

"Clinical Trials: An Introduction", JamesCare For Life Fireside Chat Meeting, Columbus, OH, 09/24/2009

"Metastatic Pancreatic Cancer", 2009 Gastrointestinal Cancers Symposium: A multidisciplinary Approach to Prevention, Diagnosis, and Treatment, Columbus, OH, 10/03/2009

"Singlet Oxygen-Mediated Protein Proximity Assay", National Cancer Institute (NCI), IMAT- Innovative Molecular Analysis Technologies Program Meeting, Bethesda, MD, 10/08/2009

"AACI Clinical Research Initiative Update", 2009 AACI CCAF Annual Meeting, Washington, D.C., 10/18/2009

"Gastrointestinal Cancer Update", 2009 Oncology Update, Columbus, OH, 10/30/2009

"Therapy for Advanced Disease and a Review of Ongoing Studies", NCCN Clinical Practice Guidelines in Oncology Symposium™: Colon and Rectal Cancers, Columbus, OH, 12/03/2009

Session Chair, Gastrointestinal Cancer 2009: A Multidisciplinary Approach to Prevention, Diagnosis and Treatment Meeting, Columbus, OH, 2009

"Hepatocellular Cancer", Hematology and Oncology Fellows Lecture, Columbus, OH, 02/02/2010

"Clinical Cancer Research at Ohio State", OSUCCC 12th Annual Scientific Retreat, Columbus, OH, 02/19/2010

2010 ASCO Review, Moderator, Columbus, OH, 06/19/2010

"AACI Clinical Research Initiative", AACI Annual Meeting, Chicago, IL, 2010

Moderator, "The Role of the Clinical Trial Medical Director", Clinical Research Initiative Annual, Chicago, IL, 07/11/2013

Moderator, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Symposium™: Colon and Rectal Cancers Meeting, Columbus, OH

Regional

"Advances in the Treatment of Colorectal Cancer", Hennepin County Medical Center Tumor Conference, 1999

"Systemic Therapy for Colorectal Cancer", Oncology for Primary Care Physicians Symposium, Rockford, IL, 1999

"Screening and Prevention of Colon Cancer", Wisconsin Ostomy Association, 2000

"University of Wisconsin Endostatin Research Program", Third Annual Wisconsin Oncology Update, Green Bay, WI, 2000

"Angiogenesis Inhibitors", Wisconsin Cancer Registrar's Annual Meeting, 2000

"Current Issues Related to Colorectal Cancer", Regional Oncology Nursing Society, Traverse Bay, MI, 2000

"Angiogenesis Inhibitors as Anticancer Agents", University of Minnesota Cancer Center Grand Rounds, Minneapolis, MN, 2000

"Colon Cancer: A Millennial Update", UWCCC Grand Rounds, 2000

"Clinical Developments with Angiogenesis Inhibitors", UWCCC Cancer Colloquium Series, 2000

"Antibodies and Angiogenesis Inhibitors as Anticancer Agents", Updates in Cancer Care, Wausau, WI, 2000

"Update in Gastrointestinal Oncology", Swedish American Hospital Cancer Series, Rockford, IL, 2001

"Advances in Colorectal Cancer", University of Wisconsin Department of Medicine Grand Rounds, 2002

"Chemoprevention of Colon Cancer", UWCCC Advances in Multidisciplinary Cancer Care, 2002

"New Approaches to Colorectal Cancer", Visiting Professor in Oncology, Traverse City, MI, 2002

"Chemoprevention: A Radical View", UWCCC Grand Rounds, 2002

"Gastrointestinal Cancers", Waukesha Memorial Hospital Cancer Center Grand Rounds, Waukesha, WI, 2002

Southeastern Wisconsin Oncology Pharmacist Society Talk (SWOPS), 11/2003

UWCCC Cancer Survivors Week Panel Member, 2003

"Metastatic Colon Cancer: Using the 'C' Word", UWCCC Grand Rounds, 2003

Cancer Residency for Clergy and Pastoral Ministries, University of Wisconsin-Madison, 2004

"Metastatic Colon Cancer: Using the 'C' Word", Cook County Hospital Visiting Professor, Chicago, IL, 2004

"Colorectal Cancer New Treatments, New Hope, New Questions", Colon Cancer Alliance Meeting, Chicago, IL, 09/15/2006

"Gastrointestinal Cancer", From Abstract to Bedside: Systematic Review of the 2007 National American Society for Clinical Oncology Meeting, Genentech, The University of Madison Wisconsin, 06/30/2007

"AACI CRI Overview and Proposed Activities", AACI Clinical Research Initiative (CRI) Meeting, Chicago, IL, 07/16/2009

"Emerging Systemic Therapies for Pancreatic Neuroendocrine Tumors", 3rd Annual M.D. Anderson Cancer Center Endocrine Surgery Symposium, Medical College of Wisconsin, 05/14/2011

"Cancer Center Experimental Therapeutics", Clinical and Translational Science Institute Cancer Center Workshop, Marquette University, 2011

"Agents and Timing of Chemotherapy for Colorectal Liver Metastases", Liver and Pancreas Symposium, Medical College of Wisconsin, 2011

"Current Drugs, Trials and Timing of Resection", Colorectal, Liver Symposium, Medical College of Wisconsin, 02/04/2012

"Targets and Shields: Improving Cancer Chemotherapy in the Post Genomic Era", La Crosse BioResearch Forum 2012, Gundersen Lutheran Medical Foundation, 02/12/2012

"Neuroendocrine Cancer – New Treatment Options", American Society of Clinical Oncology Gastrointestinal Updates and Advances in Surgical Oncology, Medical College of Wisconsin, 03/23/2013

"Timing of Regional Therapies with Systemic Chemotherapy – When to Refer", Current State of Regional Therapies for Advanced Malignancies Meeting, Medical College of Wisconsin, 08/25/2013

"Updates in Gastrointestinal Oncology", 26th Annual Update in Primary Care, Egg Harbor, WI,, 10/05/2013

Local

"Free Radicals in Medicine", Medical College of Wisconsin Medical Biochemistry Course, Milwaukee, WI, 1994

"Colon Cancer", Southeastern Wisconsin Oncology Pharmacy Oncology Association, Milwaukee, WI, 12/07/2006 - 12/10/2006

"Phase I Cancer Trials", Medical College of Wisconsin, Milwaukee, WI, 2006

Invited facilitator, 1st Annual Department of Physical Medicine and Rehabilitation Research, Medical College of Wisconsin, 2013

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

International

Thomas JP, Schiller J, Lee F, Perlman S, Friedl A, Winter T, Marnocha R, Arzoomanian R, Alberti D, Binger K, Volkman J, Feierabend C, Tutsch K, Dresen A, Auerbach R, Pluda J and Wilding G, A Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 2000

Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C, OSI-774 (Tarceva) in patients (pts) with unresectable or metastatic hepatocellular carcinoma (HCC): A multi-center Phase 2 Consortium (P2C) study, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Meeting, 2003

Philip PA, Mahoney, MR, Thomas, JP, Pitot, HC, Donehower, Kim GP, Picus, J Fitch, TR, Geyer SM, Erlichman C, Efficacy and updated tolerability of OSI-774 (Tarceva) in patients with locally advanced or metastatic biliary (BILI) carcinoma: A multi-center Phase 2 Consortium (P2C) study, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Meeting, 2003

Thomas JP, Ramanathan RK, Wilding G, Egorin MJ, Bailey H, Tutsch K, Chatta K, Tutchko S, Patel K, Renschler M, A phase 1 study of motexafin gadolinium (MGd) in combination with doxorubicin (Dox), AACR-NCI-EORTC International Conference on Molecular Targets and Cancer, 2003

Thomas JP, Wilding G, Egorin M, Bailey H, Alberti D, Tutsch K, Marnocha R, Chatta K, Tutchko S, Renschler M, Ramanathan R, A phase I and pharmacodynamic study of motefafin gadolinium (MGd) in combination with doxorubicin (Dox), AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Meeting, 2003

McNeel DG, Thomas JP, Lee FT, Friedl A, Marnocha R, Tutsch K, Volkman J, Binger K, Lakner M, Alberti DB, Eickhoff J, Wilding, G, A Phase I study of MEDI 522 in patients with advanced tumors, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Meeting, 2003

Fortune B, Kosuri K, Weatheryby L, Young D, Xu Y, Muscarella P, Ellison C, Thomas J, Bekaii-Saab T, Gemcitabine in combination with oxaliplatin in patients with advanced pancreaticobiliary cancers: The Ohio State University experience. World GI Cancer Symposium, Barcelona, Spain, 2006

T. Bekaii-Saab, A. Majumber, E. Trolli, J. Thomas, Exploring the role of CA 19-9 level as predictor of survival in patients with advanced pancreatic adenocarcinomas, The Joint ECCO 15 and 34th ESMO Multidisciplinary Congress Meeting, Berlin, Germany, 09/2009

National

- Thomas JP, Gipp J, Mulcahy RT, Induction of Gamma GlutamylCysteine Synthetase in Cells Exposed to Hydrogen Peroxide, Society of Toxicology, Seattle, WA, 1998
- Bailey HH, Thomas JP, Smith S, Smith C, Arzoomanian R, Tutsch K, Alberti D, Binger K, Feierabend C, Simon K, Kavka J, Marnocha R and Wilding G, Phase I Clinical and Pharmacokinetic Trial of 6-Hydroxymethylacylflulvene, American Society of Clinical Oncology, Atlanta, GA, 1999
- Thomas JP, Wartman MB and Bailey HH, In Vitro Cytotoxicity of HMAF with and without Buthionine Sulfoximine Against Drug-Resistant Tumor Cell Lines with Elevated Glutathione, American Association for Cancer Research, Philadelphia, PA, 1999
- Thomas JP, Schiller JS, Lee F, Perlman S, Winter T, Marnocha R, Arzoomanian R, Alberti D, Volkman J, Tutsch K, Binger K, Feierabend C, Dresen A, Auerbach R and Wilding G, A Phase I and Pharmacokinetic Study of Recombinant Human Endostatin, American Association for Cancer Research, New Orleans, LA, 2001
- Tutsch, K, Thomas, J.P., Van Ummersan, L., Marnocha R, Arzoomanian R, Alberti D, Volkman J, Binger K, Feierabend C, Dresen A and Wilding G, A Phase I Pharmacodynamic Trial of Perifosine, NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Miami, FL, 2001
- Thomas JP, Arzoomanian R, Alberti D, Geiger P, Marnocha R, Tutsch K, Dresen A, Volkman J, Binger K, Kolb M, Feierabend C, Black S, Hampton K, Wilding G, A Phase I and Pharmacodynamic Study of the Proteasome Inhibitor PS-341 in Combination with Doxorubicin, American Society of Clinical Oncology 38th Annual Meeting, Orlando, FL, 2002
- Wong SJ, Sadasivan C, Erickson B, Ota D, Mulkerin D, Thomas J, Holen K, Meadows S, Ritch P, Telford G, Redlich P, Gore E, A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer, 2003
- Thomas JP, Geiger PG, Redox reactions in the uptake and cytotoxicity of motexafin gadolinium, American Association for Cancer Research Meeting, 2004
- Saltz, LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Carver G, Mayer, RJ, Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803), American Society of Clinical Oncology Meeting, New Orleans, LA, 2004
- Huie M, Greiner L, Thomas JP, Mulkerin DL, Smith R, Welsh J, McDermott J, Neider R, Bianco J, Holen KD, Institutional series of selective internal radiation therapy (SIRT) for liver predominant metastatic colorectal cancer (MCRC), American Society of Clinical Oncology Meeting, New Orleans, LA, 2004
- Wong SJ, Sadasivan C, Erickson B, Ota D, Mulkerin DL, Thomas JP, Holen KD, Meadows S, Telford G, Gore E, A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer, American Society of Clinical Oncology Meeting, New Orleans, LA, 2004
- Philip PA, Mahoney M, Thomas JP, Pitot H, Donehower R, Kim G, Picus J, Fitch T, Geyer S, Erlichman C, Phase II Trial of Erlotinib (OSI-774) in patients with hepatocellular or biliary cancer, American Society of Clinical Oncology Meeting, New Orleans, LA, 2004
- Hegeman, R.B., Mulkerin, D., Thomas, J.P., Alberti, D., Marnocha, R., Kolesar, J. and Wilding G, Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU) leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors, American Society for Clinical Oncology Meeting, Orlando, FL, 2005
- Thomas JP, Geiger P, Weichert J, Evaluation of the neovascular toxin AVE8062A by microCT with a novel blood pool contrast agent, American Association for Cancer Research Meeting, Anaheim, CA, 2005
- Richards, D.A., Oettle, H., Vervenne, W.L., Saif, M.W., Thomas, J., Spitzer, G., Enas. N. and Weitzman A., Randomized double-blind trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas, American Society for Clinical Oncology Meeting, Orlando, FL, 2005
- Groteluschen D, Mahoney MR, Pitot HC, Laheru D, Kolesar J, Thomas JP, Erlichman C, Holen KD, A Multicenter Phase 2 Consortium (P2C) Study of Triapine in Patients (Pts) with Advanced Adenocarcinoma of the Pancreas, American Society for Clinical Oncology Meeting, Atlanta, GA, 2006
- Schelman, W, Holen, K, Alberti, D, Kolesar, J, Thomas J, A Phase I Study of Triapine in Combination with irinotecan in Refractory Tumors, American Society for Clinical Oncology Meeting, Atlanta, GA, 2006

- Bekaii-Saab TS, Kosuri K, Campbell J, Thomas J, Villalona-Calero M, A phase I dose escalation study of pharmacobiologically based scheduling of capecitabine and mitomycin C (MMC) in patients with gastrointestinal solid malignancies, Gastrointestinal Cancers Symposium, Orlando, FL, 2007
- Kosuri K, Weatherby D, Young D, Bloomston M, Muscarella P, Ellison C, Thomas J, Bekaii-Saab TS., A single center retrospective study of gemcitabine and oxaliplatin in patients with advanced pancreas cancer, Gastrointestinal Cancers Symposium, Orlando, FL, 2007
- Choi B, Holen K, Alberti D, Schelman W, Kolesar J, Thomas J, Antholine W, Marnocha R, Eickhoff J, Wilding G, A Dose Escalation and Biologic Study of Triapine in Combination with Irinotecan For Patients with Refractory Solid Tumors, American Society for Clinical Oncology Annual Meeting, Chicago, IL, 2007
- B.S. Choi, K.D. Hoen, D. Alberti, W. Schelman, J. Kolesar, J.P. Thomas, W. Antholine, R. Marnocha, J., The maximum tolerated dose and biologic effects of 3-amino-pyridine-2-carboxaldehyde thiosemicarbazone (T) in combination with Irinotecan (I) for patients with refractory solid tumors., American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 01/2008
- D.M. Dilts, A.B. Sandler, S. Cheng, J. Crites, L. Ferranti, A. Wu, M.A. Bookman, J.P. Thomas, J. Ostroff., Accrual to clinical trials at selected comprehensive cancer centers, American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 01/2008
- N. K. LoConte, K.D. Holen, M.R. Mahoney, D. W. Szydlo, J. Picus, W. Maples, H. Pitot, P.A. Philip, J.P. Thomas, C.E. Erlichman, Interim report of a multicenter phase II clinical trial testing a combination of biweekly bevacizumab and daily Erlotinib in patients with metastatic bile tract carcinoma: A Phase II Consortium (P2C) Study., American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 01/2008
- Hill M, Kosuri K, Li X, Thomas J, Zalupski M, Bekaii-Saab T, A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTx) in patients with metastatic adenocarcinoma of the pancreas (MAP), American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 01/2008
- K.D. Holen, M.R. Mahoney, N.K. LoConte, D.W. Szydlo, J. Picus, W.J. Maples, G.P. Kim, H.C., Pitot, P.A. Philip, J.P. Thomas, C.E. Erlichman, Efficacy report of a multicenter phase ii trial testing a biologic-only combination of biweekly bevacizumab and daily Erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) Study, American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 01/2008
- CR Balint, KA Blum, W Blum, JC Byrd, WE Carson, KK Chan, C-S Chen, D Cohn, B Fischer, AJ Johnson, C Kefauver, MV Knopp, GB Lesinski, DM Lucas, D O'Malley, G Marcucci, GA Otterson, MA Phelps, B Ravaswamy, LJ Schaaf, MH Shah, C Shapiro, J Thomas, MA Villalona-Calero, and D Wilkins., Phase I Trials of Ant-Cancer Agents: The Ohio State University National Cancer Institute (NCI) U01 CA 076576 MR Grever, MD, Principal Investigator, National Cancer Institute (NCI) Translational Meeting, Washington, DC, 2008
- Martin LK, Li X, Kim SE, Balint C, Kosuri K, Thomas JP, Zalupski M, Bekaii-Saab TS, A Multicenter Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, American Association for Cancer Research Meeting, Denver, CO, 04/2009
- M.B. Lustberg, J. Nuovo, J.P. Thomas, P.J. Monk, S. Kim, M. Villalona-Calero, T. Bekaii-Saab, Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: a dose-escalating phase I study, American Society for Clinical Oncology 2009 Annual Meeting, Orlando, FL, 05/2009
- CR Balint, KA Blum, W Blum, JC Byrd, WE Carson, KK Chan, C-S Chen, D Cohn, B Fischer, AJ Johnson, C Kefauver, MV Knopp, GB Lesinski, DM Lucas, D O'Malley, G Marcucci, GA Otterson, MA Phelps, B Ravaswamy, LJ Schaaf, MH Shah, C Shapiro, J Thomas, MA Villalona-Calero, and D Wilkins, Phase I Trials of Ant-Cancer Agents: The Ohio State University National Cancer Institute (NCI) U01 CA 076576 MR Grever, MD, Principal Investigator, National Cancer Institute (NCI) Translational Meeting, Vienna, VA, 2009
- L. Katherine Martin, Xiaobai Li, Sharon E. Kim, Catherine R. Balint, Kavitha V. Kosuri, James P. Thomas, Mark M. Zalupski, Tanios Bekaii-Saab, A multi-center phase II study of the combination of bevacizumab, fixed dose rate gemcitabine, and infusional 5-fluorouracil in patients with advanced pancreas cancer, Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009
- Tanios Bekaii-Saab, Mitch Phelps, Xiaobai Li, Motoyasu Saji, Kavitha Kosuri, Laura Goff, John Kauh, Bert O'Neil, Christopher South, James Thomas, Stephanie Balsom, Nicole Chattah, Catherine Balint, Ryan

Liersemann, Vasily Vasko, William Marsh, L. Austin Doyle, Matthew Ringel, Miguel A. Villalona., A Multi-institutional Study of AZD6244 in Patients with Advanced Biliary Cancers, Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009

Regional

Nag Subir, Kennedy Andrew, Salem Riad, Murthy Ravi, McEwan Alexander, Nutting Charles, Benson AI, Espat Joseph, Ignacia Bilbao, Sharma Ricky, Thomas James, Coldwell Douglas, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology, IL, 2007

Choi B, Holen K, Alberti D, Schelman W, Kolesar J, Thomas J, Antholine W, Marnocha R, Eickhoff J, Wilding G, A Dose Escalation and Biologic Study of Triapine in Combination with Irinotecan For Patients with Refractory Solid Tumors. ASCO Annual Meeting, Chicago, IL, 2007

Local

Wong SJ, Sadasivan C, Erickson B, Ota D, Mulkerin D, Thomas JP, Holen K, Meadows S, Telford E, Gore E., A Phase II Trial Of Pre-Operative Capecitabine and Concurrent Radiation for Locally Advanced Rectal Cancer, Medical College of Wisconsin, Milwaukee, WI, 2003

Thomas A. Giever, Arjun Ranade, James P. Thomas, Paul S. Ritch, George Haasler, Mario Gasparri, David Johnstone, Elizabeth Gore, Cnadice Aitken Johnstone, Kuwinder Dua, Abdul Khan, Young Oh, Ben George; Medical College of Wisconsin, Milwaukee, WI; Rosiland Franklin University of Medicine and Science, North Chicago, IL, Utility of invasive staging procedures in patients (pts) with localized esophageal cancer (EC)., 2015 Gastrointestinal Cancers Symposium, ASCO University, - 10/15/2015

Nicholas G Berger, Bradford Kim, Sepideh Gholami, Georgios A Margonis, Cecillia Ethun, Jack P Silva, Susan Tsai, Kathleen K. Christians, Harveshp Mogal, Callisia Clarke, Shishir Kumar Maitthel, Timoty Pawlik, Michael Ian D'Angelica, Thomas A. Aloia, T. Clark Gamblin; Medical College of Wisconsin, Milwaukee, WI; MD Anderson Cancer Center, Houston, TX; Memorial Sloan Kettering Cancer Center, New York, NY, Decision of Surgical Oncology, Department of Surgery, John Hopkins University School of Medicine, Baltimore, MD; Emory University School of Medicine, Atlanta, GA; Ohio State University, Columbus, OH; The University of Texas MD Anderson Cancer Center, Houston, TX, Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review., 2017 Gastrointestinal Cancer Symposium, ASCO University Gastrointestinal Cancer Symposium, - 01/20/2017

Shinoj Pattali Jayavalsan, Shannon Leah Schmidt, Vipal Durkal, Paul S. Ritch, James P. Thomas, Beth Erickson, Kathleen K. Christians, Susan Tsai, Douglas B. Evans, Ben George; Medical College of Wisconsin, Milwaukee, WI; Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI, Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?, 2016 Gastrointestinal Cancers Symposium, ASCO University, - 01/22/2016

John Maclou Longo, Malika Lisa Siker, Ben George, Lauren Kosinski, Kirk A. Ludwig, Mary F. Otterson, James P. Thomas, Lauren Allison Wiebe, Beth Erickson; Medical College of Wisconsin, Milwaukee, WI, Helical tomotherapy with concurrent chemotherapy in the treatment of anal canal carcinoma: A review of clinical outcomes at the tertiary referral center., 2014 Gastrointestinal Cancers Symposium, ASCO University, - 01/18/2014

Shannon Leah Schmidt, Vipal Durkal, Shinoj Pattali Jayavaslan, James P. Thomas, Paul S. Ritch, Beth Erickson, Kathleen K. Christians, Susan Tsai, Douglas B. Evans, Ben George; Medical College of Wisconsin, Milwaukee, WI; Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI, Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG)., 2016 Gastrointestinal Cancer Symposium, ASCO University, - 01/22/2016

Shannon Leah Schmidt, Vipal Durkal, Shinoj Pattali Jayavalsan, Paul S. Ritch, James P. Thomas Beth Erickson, Kathleen K. Christians, Susan Tsai, Douglas B. Evans, Ben George; Medical College of Wisconsin, Milwaukee, WI; Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI, Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?, 2016 Gastrointestinal Cancers Symposium, ASCO University, - 01/22/2016

John Thomas Miura, Ashley N. Krepline, Kaleb D. Duelge, Ben George, Paul S. Ritch, Beth Erickson, James P. Thomas, Anna Mahmoud, Edward J. Quebbeman, Kiran Turaga, Fabian McCartney Johnston, Kathleen K. Christians, T. Clark Gamblin, Douglas B. Evans, Susan Tsai; Medical College of

Wisconsin, Milwaukee, WI, Neoadjuvant therapy for pancreatic cancer in patients older than age 75, 2014 Gastrointestinal Cancers Symposium, ASCO University, - 01/17/2014
Ben George, Mark Bailey, Alexa Betzig Schrock, Lauren Thrope, Laurie M. Gay, Paul S. Ritch, James P. Thomas, Beth Erickson, Susan Tsai, Kathleen K. Christans, Douglas B. Evans, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Aatur D. Singhi, Siraj Mahamed Ali; Medical College of Wisconsin, Milwaukee, WI; Foundation Medicine, Inc., Cambridge, MA; Foundation Medicine, Cambridge, MA; Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Department of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC), 2017 Gastrointestinal Cancers Symposium, ASCO University Gastrointestinal Cancers Symposium, - 01/20/2017

COMMITTEE SERVICE:

Medical College of Wisconsin

2011 - 2013 Member, Dean's Data Warehouse Committee, Medical College of Wisconsin
2011 - Present Member, Cancer Center Strategic Planning Committee, Froedtert and
2012 - 2013 Member, Performance Management Technology Work Group
2012 - Present Member, Molecules to Cells Advisory Committee, Medical College of Wisconsin
2013 - Present Member, Cancer Center IT Strategic Planning Committee
2013 - Present Co-leader, Research Strategy: Cancer Work Group
2013 - Present Member, Senior Associate Dean for Research Search Committee,

Hospital

2010 - 2012 Radiology Chair Search Committee, Medical College of Wisconsin
2010 - Present Clinical Trials Office Working Committee, Cancer Center, Medical College of Wisconsin
2010 - 2011 Clinical Trials Management Software Evaluation Committee, Cancer Center, Medical College of Wisconsin
2010 - Present Associate Director, Clinical Investigation, Cancer Center, Medical College of Wisconsin
2011 - 2012 Member, Vice Chair of Department of Medicine and Division Manager of Medicine, VA Search Committee, Medical College of Wisconsin
2011 - 2012 Member, Cancer Center Service Line Director Search Committee, Clinical Cancer Center, Medical College of Wisconsin
2011 - Present Co-Chair, Medical College Physician (MCP) Strategic Planning Committee: Integrate Research into Clinical Programs, Medical College of Wisconsin
2011 - Present Clinical Operations Committee, Clinical Cancer Center, Medical College of Wisconsin

MCW TEACHING ACTIVITIES:

Medical Student Education

1985 - 1987 Biochemistry Tutor
1991 - 1994 Biochemistry Instructor, Course Designer: Problem Based Learning Section
1993 - 1995 Instructor, Introduction to Clinical Medicine (M-2), Department of Medicine
2011 - 2012 Lecturer, Advanced Genetics: Cancer Cell Biology Course MMG 053521
2012 - Present Instructor, Molecules to Cells (M-2), Department of Biochemistry

EXTRAMURAL TEACHING:

Medical Student Education

1997 University of Wisconsin Medical School, Madison, WI, Lecturer, Oncology 703, McArdle Laboratory for Cancer Research, Department of Oncology
2003 - Present University of Wisconsin Medical School, Madison, WI, Instructor, Patient, Doctor and Society
2003 - 2005 University of Wisconsin Medical School, Madison, WI, Lecturer, Radiobiology, Department of Human Oncology
2003 University of Wisconsin Medical School, Madison, WI, Lecturer, Neoplasia (M-2)
2004 University of Wisconsin Medical School, Madison, WI, Lecturer, Toxicology 308

Resident and Fellow Education

- 2003 - 2005 Cancer Residency for Clergy and other Pastoral Caregivers
- 2005 - 2012 Lecturer, Hematology Oncology Fellowship Program Didactic Program and Board Review Program
- 2012 - Present Hematology Oncology Fellowship Program Didactic Review
- 2012 - Present Lecturer, Department of Surgery Resident Training, "Updates in Systemic Therapy for Metastatic Neuroendocrine Tumors"

COMMUNITY SERVICE ACTIVITIES:

- 02/27/2001 "Cancer Warrior" Aired on PBS, Nova Online, James P. Thomas, Chapter Eight: Clinical Trials: from mouse to man, early results, the future.
- 05/06/2008 Key Advocate, Clinical Trials Legislation, 127th General Assembly, Senate Bill 186.
- 09/08/2008 "Lack of Volunteers Slows Progress of Cancer Research". Video/News Release broadcast in 359 media outlets nationwide.
- 10/08/2008 - 10/13/2008 Knights of Malta's Medical Mission, ILAC Mission Trip, Santiago, Dominican Republic
- 01/2009 "Cancer trials need volunteers" article in Ohio State Alumni Magazine January - February Issue. www.jamesline.com
- 03/14/2009 L.A. Times Interview with Shari Roan. "Medical clinical research slows for lack of patients".
- 03/16/2009 It's All About Health radio program, Guest Speaker "Colorectal cancer and the disparity in African Americans". Radio Program on Joy 106.3 with host Dr. William Hicks. Air date: 3/21/09
- 05/08/2009 WBNS-TV/Channel 10 Story. "Drug Shortages Cost Millions, Threaten Lives" Air Date: 5/08/09. http://www.10tv.com/live/content/local/stories/2009/05/08/story_drugs.html?sid=102
- 11/12/2009 - 11/16/2009 Knights of Malta's Medical Mission, ILAC Mission Trip, Santiago, Dominican Republic
- 03/2011 Invited Speaker, Colorectal Cancer Awareness Event, "Chemotherapy for Colon and Rectal Cancer: SO Much More to Offer," Department of Surgery, Medical College of Wisconsin
- 03/08/2014 Participant, Second Ellen's Icebreaker Polar Plunge. Nagawicka Lake, WI
- 03/15/2014 Invited speaker, CRC Awareness Event Spring Fest, Hamilton High School, Sussex, WI

COMPANIES OWNED:

- 2006 - Present Founder & CEO, Percitus Biosciences, LLC. Suite 104, 3587 Anderson Street, Madison, WI 53704 <http://www.percitusbio.com/news.htm>

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Girotti AW, **Thomas JP**. Damaging Effects of Oxygen Radicals on Resealed Erythrocyte Ghosts. *J Biol Chem.* 259:1744-1752, 1984.
2. Girotti AW, **Thomas JP**. Superoxide and Hydrogen Peroxide-Dependent Lipid Peroxidation in Intact and Triton-Dispersed Erythrocyte Membranes. *Biochem.Biophys. Res.Comm.* 118:474-48, 1984.
3. Girotti AW, **Thomas JP**, Jordan JE. Lipid Peroxidation in Erythrocyte Ghosts: Sensitization of the Membranes toward Ascorbate- and Superoxide-induced Peroxidation and Lysis. *Arch Biochem Biophys.* 236:238-25, 1985.
4. Girotti AW, **Thomas JP**, Jordan JE. Prooxidant and Antioxidant Effects of Ascorbate on Photosensitized Peroxidation of Lipids in Erythrocyte Membranes. *Photochem Photobiol.* 41:267-276, 1985.
5. Girotti AW, **Thomas JP**, Jordan JE. Inhibitory Effect of Zinc (II) on Free Radical Lipid Peroxidation in Erythrocyte Membranes. *J Free Rad Biol Med.* 1: 395-401, 1985.
6. Girotti AW, **Thomas JP**, Jordan JE. Xanthine Oxidase-Catalyzed Cross-linking of Cell Membrane Proteins. *Arch Biochem Biophys.* 251: 639-653, 1986.
7. **Thomas JP**, Bachowski GJ, Girotti AW. Inhibition of Cell Membrane Lipid Peroxidation by Cadmium and Zinc-Metallothioneins. *Biochemica et Biophys Acta.* 884: 448-461, 1986.
8. Kalyanaraman B, Feix JB, Seiber F, **Thomas JP**, Girotti AW. Photodynamic Action of Merocyanine-540 on Artificial and Natural Cell Membranes: Involvement of Singlet Molecular Oxygen. *Proc Natl Acad Sci. (USA)* 84: 2999-3003, 1987.

9. **Thomas JP**, Hall RD, Girotti AW. Singlet Oxygen Intermediacy in the Photodynamic Action of Membrane-Bound Hematoporphyrin Derivative. *Cancer Lett.* 35: 295-302, 1987.
10. Farber NE, Pieper GM, **Thomas JP**, Gross GJ. Beneficial Effects of Iloprost in the Stunned Canine Myocardium. *Circ. Res.* 62: 204-21, 1988.
11. Bachowski GJ, **Thomas JP**, Gross GJ. Ascorbate-Enhanced Lipid Peroxidation in Photooxidized Cell Membranes: Cholesterol Product Analysis as a Probe of Reaction Mechanism. *Lipids* 23: 580-586, 1988.
12. **Thomas JP**, Girotti AW. Photo oxidation of Cell Membranes in the Presence of Hematoporphyrin Derivative: Reactivity of Phospholipid and Cholesterol Hydroperoxides with Glutathione Peroxidase. *Biochem Biophys Acta.* 962: 297-307, 1988.
13. **Thomas JP**, Girotti AW. Reactivity of Photochemically-Generated Lipid Hydroperoxides in Cell Membranes with Glutathione Peroxidase. *Photochem Photobiol* 49:153-156, 1989.
14. **Thomas JP**, Girotti AW. Role of Lipid Peroxidation in Hematoporphyrin Derivative-sensitized Photokilling of Tumor Cells: Protective Effects of Glutathione Peroxidase. *Cancer Res.* 49:1682-1686, 1989.
15. **Thomas JP**, Girotti AW. Glucose Administration Augments In Vivo Uptake and Phototoxicity of the Tumor-Localizing Fraction of Hematoporphyrin Derivative. *Photochem Photobiol* 49:241-247, 1989.
16. **Thomas JP**, Maiorino M, Ursini F, Girotti AW. Protective Action of Phospholipid Hydroperoxide Peroxidase Against Membrane-Damaging Lipid Peroxidation: In Situ Reduction of Phospholipid and Cholesterol Hydroperoxides. *J Biol Chem* 265: 454-461, 1990.
17. **Thomas JP**, Maiorino M, Geiger PJ, Ursini F, Girotti AW. Reduction of Phospholipid and Cholesterol Hydroperoxides by Phospholipid Hydroperoxide Peroxidase. *Biochem Biophys Acta.* 1045: 252-260, 1990.
18. Maiorino M, **Thomas JP**, Girotti AW, Ursini F. Reactivity of Phospholipid Hydroperoxide Glutathione Peroxidase with Membrane and Lipoprotein Lipid Hydroperoxides. *Free Rad Res Commun* 12: 131-135, 1991.
19. Geiger PG, **Thomas JP**, Girotti AW. Lethal Damage to Murine L1210 Cells by Exogenous Lipid Hydroperoxides: Protective Role of Glutathione-Dependent Selenoperoxidases. *Arch Biochem Biophys* 288: 671-680, 1991.
20. Girotti AW, **Thomas JP**, Geiger PG. Role of Selenoperoxidases in Cytoprotection Against Photooxidative Damage. In: *Oxidative Damage and Repair: Clinical, Biological and Medical Aspects.* (K.J.A. Davies ed.) 331-335, Pergamon Press, New York 1991.
21. Whelan HT, Traul DL, Przybylski C, Segura A, **Thomas JP**, Meyer G, Sieber F. Interactions of Merocyanine 540 with Tumor Brain Cells. *Ped Neur* 8:117-120, 1992.
22. **Thomas JP**, Geiger PG, Girotti AW. Lethal Damage to Endothelial Cells by Oxidized Low Density Lipoprotein: Role of Selenoperoxidases in Cytoprotection Against Lipid Hydroperoxide- and Iron-Mediated Reactions. *J Lipid Res* 34: 479-490, 1993.
23. Lin F, **Thomas JP**, Girotti AW. Hyperexpression of Catalase in Selenium-Deprived Murine L1210 Cells. *Arch Biochem Biophys* 305: 176-185, 1993.
24. Konorev EA, Struck AT, Baker JE, Ramanujam S, **Thomas JP**, Radi R, Kalyanarman B. Intracellular Catalase Inhibition Does Not Predispose Rat Heart to Ischemia-Reperfusion and Hydrogen Peroxide-Induced Injuries. *Free Rad Res Commun* 19: 397-407, 1993.
25. **Thomas JP**, Kalyanarman, Girotti AW. Involvement of Pre-existing Lipid Hydroperoxides in Cu²⁺-Stimulated Oxidation of Low-Density Lipoprotein. *Arch Biochem Biophys* 315: 244-254, 1994.
26. Whelan HT, Schmidt BA, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, **Thomas JP**, Meyer GA. The Role of Photodynamic Therapy in Posterior Fossa Brain Tumors: A Pre-Clinical Study in a Canine Glioma Model. *J. Neurosurg.* 79: 562-568, 1994.
27. Struck AT, Hogg N, **Thomas JP**, Kalyanarman B. Nitric Oxide Donor Compounds Inhibit the Toxicity of Oxidized Low-Density Lipoprotein to Endothelial Cells. *FEBS Lett.* 361: 291-29, 1995.
28. Carbone PP, Douglass JA, **Thomas JP**, Tutsch K, Pomplun M, Hamielec M, Pauk, D. Bioavailability Study of Oral Liquid and Tablet Forms of α -Difluormethylornithine. *Clin Cancer Res* 6: 3850-3854, 2000.
29. Mundhenke C, **Thomas JP**, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A. Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin. *Clin Cancer Res* 7: 3366-3374, 2001.
30. Carbone PP, Douglass JA, **Thomas JP**, Tutsch K, Pomplun M, Hamielec M, Pauk D. Phase I Study of α -Difluormethylornithine in Solid Organ Transplant Patients. *Cancer Epi Bio Phar* 10: 657-661, 2001.
31. **Thomas JP**, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith

- C, Smith S, MacDonald J, Wilding G, Bailey H. Phase I Clinical and Pharmacokinetic Trial of Irofulan. *Cancer. Chemother Pharmacol* 4: 467-472, 2001.
32. Ochoa L, Hurwitz HI, Wilding G, Cohen D, **Thomas JP**, Schwartz G, Monroe P, Petros WP, Ertel V, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky K. Pharmacokinetics and Bioequivalence of a Combined Oral Formulation of Eniluracil, an Inactivator of Dihydropyrimidine Dehydrogenase, and 5-fluorouracil in Patients with Advanced Malignancies. *Annals of Oncology*, 11: 1313-1322, 2002.
 33. Berlin JD, Catalano P, **Thomas JP**, Kugler JW, Haller DG, Benson AB III. Phase III Study of Gemcitabine in Combination with 5-FU vs. Gemcitabine Alone in Patients with Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. *J Clin Oncol* 20: 3270-3275, 2002.
 34. Merchant JJ, Tutsch KD, Dresen A, Arzoomanian RZ, Alberti D, Feierabend C, Binger K, Marnocha R, **Thomas JP**, Cleary J, Wilding G. Phase I Clinical and Pharmacokinetic Study of NSC 655649, A Rebeccamycin Analogue, Given in Both Single-Dose and Multiple-Dose Formats. *Clin Cancer Res* 8: 2193-2201, 2002.
 35. Morgan-Meadows S, **Thomas JP**, Mulkerin DM, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marnocha R, Arzoomanian R, Wilding G. Phase I Study of Eniluracil, oral 5-Fluorouracil and Gemcitabine in Patients with Advanced Malignancy. *Invest. New Drugs* 20:377-82, 2002.
 36. **Thomas JP**, Tutsch KD, Cleary JF, Arzoomanian R, Alberti D, Simon K., Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I Clinical and Pharmacokinetic Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol *Cancer Chemother. Pharm* 50:465-72, 2002.
 37. Morgan-Meadows S, Mulkerin D, Berlin J, Warren D, **Thomas JP**. A Phase II Trial of Perillyl Alcohol in Patients with metastatic Colorectal Cancer. *Int J Gastrointest Cancer* 32(2-3):125-8, 2002.
 38. **Thomas JP**, Schiller J, Lee F, Perlman S, Friedl A, Winter T, Marnocha R, Arzoomanian R, Alberti D, Binger K, Volkman J, Feierabend C, Tutsch K, Dresen A, Geiger PG, Pluda J, Wilding G. A Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin. *J Clin Onc* 21: 223-31, 2003.
 39. Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, and **Thomas JP**. Gemcitabine, Paclitaxel, and Piritrexim: A Phase 1 study. *Amer. J. Clin. Oncol* 26(3): 280-4, 2003.
 40. Shepard RC, Levy D, Berlin J, Stuart K, Harris J, Aviles V, **Thomas JP**, Benson AB. A Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298): A trial of the Eastern Cooperative Oncology Group. *Oncology* 66 (4):303-9, 2004.
 41. Morgan-Meadows SM, Mulkerin DM, Berlin JD, Warren D, Inman A, **Thomas JP**. A phase II trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma. *Oncology* 69(2):130-4, 2005.
 42. Huie M, Liu G, Carducci M, Wilding G, **Thomas JP**. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. *Am. J. Oncology* 26(3):280-4, 2003.
 43. Dy GK, **Thomas JP**, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger, K, Pitot HC, Alberts SR, Hanson LJ, Kaufman SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. *Clin Cancer Res.* 11(9): 3410-6, 2005 May 1.
 44. Philip PA, Mahoney MR, Allmer C, **Thomas JP**, Pitot HC, Kim G, Donehower R, Fitch T, Picus J, Erlichman C. Phase II Study of Erlotinib (OSI-774) in Patients with Advanced Hepatocellular Cancer. *J. Clin. Oncol* 23(27):6657-63, 2005 September 20.
 45. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, **Thomas JP**, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, and Wilding G. Phase I trial of a monoclonal antibody specific for $\alpha v \beta 3$ integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. *Clin Cancer Res.* 11(21):7851-60, 2005 Nov 1.
 46. Huie M, Carducci M, Liu G, Wilding G, Marnocha R, Izquierda M, **Thomas J**. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. *Am J of Clinical Oncology.* 28 (6):613-617, 2005 Dec.
 47. Philip PA, Mahoney MR, Allmer C, **Thomas J**, Pitot HC, Kim G, Donehower RC, Fitch T. Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced biliary cancer. *J Clin Oncol* 2006;24(19):3069-3074.
 48. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, **Thomas J**, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. *J. Clin. Oncol.* 24: 3535 - 3541,

2006 Aug 1.

49. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat Bilbao JI, Sharma RA, **Thomas JP**, Coldwell D. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report From The Radioembolization Brachytherapy Oncology Consortium (REBOC). *Intl J. Radiation, Oncology, Biology, Physics.* 68(1):13-23, 2007 May 1.
50. Bailey HH, Alberti DB, **Thomas JP**, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G. A Phase I Trial of weekly administered BMS-214662 and paclitaxel *Clin Cancer Res.* 13(12):3623-9. 2007 June 15
51. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, **Thomas JP**, Fields Anthony LA, Carver G, Mayer RJ, for the Cancer and Leukemia Group B. Irinotecan Fluorouracil and Leucovorin is not superior to Fluorouracil and Leucovorin Alone as Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 *J. Clin Oncol.* 25: 3456-61, 2007 August 10.
52. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, **Thomas J.**, Fuchs CS. Association of dietary pattern with cancer recurrence and survival in patients with stage III colon cancer, [Journal Article. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't] *JAMA.* 298(7):754-64, 2007.
53. Attia S, Holen KD, **Thomas JP**, Richie K, Dzelak T, Teeter K, Warren D, Bliger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. *Clin Adv Hematol & Oncol.* 6(1):44-54, 2008 January.
54. W, Morgan-Meadows S, Bailey H, Holen K, **Thomas JP**, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 62(4):727-733, 2008 Sep.
55. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, **Thomas JP**, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. *Journal of Inorganic Biochemistry.* 102(4):693-8, 2008 Apr.
56. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, **Thomas J**, Berlin J. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. *Investigational New Drugs.* 26(3):241-7, 2008 Jun.
57. Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, **Thomas J**, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. *JAMA.* 299(21):2515-23, 2008 Jun 4.
58. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, **Thomas J**, Fuchs CS, Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. [see comment]. [Journal Article. Randomized Controlled. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't] *Journal of Clinical Oncology.* 26(25):4109-15, 2008 Sep 1.
59. LoConte NK, **Thomas JP**, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A Phase I pharmacodynamic trial of Bortezomib in Combination with Doxorubicin in patients with advanced cancer. *Cancer Chemother Pharmacol* 63(1):109-15. December 2008
60. Fortune BE, Li X, Kosuri KV, Weatherby LM, **Thomas JP**, Bekaii-Saab TS. Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study. *Oncology.* 76(5):333-7, 2009.
61. Saif WM, Oettle H., Vervenne WL, **Thomas JP**, Spitzer G, Visseren-Grul C, Enas N, Richards DA. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 vs. gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. *Cancer Vol.* 15:1-5. July/August 2009 No. 4.
62. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti, MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr., Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, **Thomas J**, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. *JNCCN.* 7(8):838-81, September 2009.
63. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti, MA, Cooper HS, Covey A, Dilawari RA, Early

- DS, Enzinger PC, Fakhri MG, Fleshman J Jr., Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, **Thomas J**, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. JNCCN. 7(8):778-831, September 2009.
64. Mulkerin D, LoConte NK, Holen KD, **Thomas JP**, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest. New Drugs 27(5):461-8. October 2009.
65. Bekaii-Saab T., Hill M, Campbell A., Kosuri K., **Thomas J.**, Villalona-Calero M. A phase I dose escalation of a pharmacobiologically based scheduling of capecitabine and Mitomycin C in patients with gastrointestinal malignancies. Cancer Chemother Pharmacol 65(5):863-9. April 2010.
66. Choi B, Alberti D, Schelman W, Kolesar J, **Thomas J**, Marnocha R, Eickhoff J, Ivy S, Wilding G, Holen K. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2009 (Epub ahead of print).
67. Lubner SJ, LoConte NK, Holen KD, Schelman W, **Thomas JP**, Eickhoff JC, Mulkerin, DL. A phase II study of oxaliplatin, 5-FU, leucovorin and 2 days of high-dose oral capecitabine in patients with metastatic colorectal cancer. Clinical Colorectal Cancer 2009; (Accepted).
68. Traynor AM, **Thomas JP**, Ramanathan RK, Mody TD, Alberti D, Wilding G, and Bailey HH. Phase I Trial of Motexafin Gadolinium and Doxorubicin in the Treatment of Advanced Malignancies. Invest. New Drugs. 29(2):316-22, 2011 April.
69. Cornell, R.F, Kelly, D.F., Kim, J., Bordo, G., Duong, H.T., Thomas, J.P., Wong, Y.L., Carroll, T.B. and Findling, J.W. Chemotherapy-Induced regression of an adrenocorticotropin (ACTH)-Secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. (submitted).
70. Geiger PG, **Thomas JP**, Girotti AW. Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. Arch Biochem Biophys. 1991 Aug 01;288(2):671-80.
71. **Thomas JP**, Geiger PG, Maiorino M, Ursini F, Girotti AW. Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim Biophys Acta. 1990 Aug 06;1045(3):252-60.
72. Maiorino M, **Thomas JP**, Girotti AW, Ursini F. Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. Free Radic Res Commun. 1991;12-13 Pt 1:131-5.
73. **Thomas JP**, Maiorino M, Ursini F, Girotti AW. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. J Biol Chem. 1990 Jan 05;265(1):454-61.
74. Farber NE, Pieper GM, **Thomas JP**, Gross GJ. Beneficial effects of iloprost in the stunned canine myocardium. Circ Res. 1988 Feb;62(2):204-15.
75. **Thomas JP**, Girotti AW. Reactivity of photochemically-generated lipid hydroperoxides in cell membranes with glutathione peroxidase. Photochem Photobiol. 1989 Feb;49(2):153-6.
76. **Thomas JP**, Girotti AW. Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. Cancer Res. 1989 Apr 01;49(7):1682-6.
77. **Thomas JP**, Girotti AW. Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. Photochem Photobiol. 1989 Mar;49(3):241-7.
78. Whelan HT, Traul DL, Przybylski C, Segura A, **Thomas J**, Meyer G, Sieber F. Interactions of merocyanine 540 with human brain tumor cells. Pediatr Neurol. 1992;8(2):117-20.
79. **Thomas JP**, Girotti AW. Photooxidation of cell membranes in the presence of hematoporphyrin derivative: reactivity of phospholipid and cholesterol hydroperoxides with glutathione peroxidase. Biochim Biophys Acta. 1988 Oct 14;962(3):297-307.
80. **Thomas JP**, Hall RD, Girotti AW. Singlet oxygen intermediacy in the photodynamic action of membrane-bound hematoporphyrin derivative. Cancer Lett. 1987 Jun;35(3):295-302.
81. Girotti AW, **Thomas JP**, Jordan JE. Lipid photooxidation in erythrocyte ghosts: sensitization of the membranes toward ascorbate- and superoxide-induced peroxidation and lysis. Arch Biochem Biophys. 1985 Jan;236(1):238-51.
82. Kalyanaraman B, Feix JB, Sieber F, **Thomas JP**, Girotti AW. Photodynamic action of merocyanine 540 on artificial and natural cell membranes: involvement of singlet molecular oxygen. Proc Natl Acad Sci U S A. 1987 May;84(9):2999-3003. PMID: PMC304788

83. Bachowski GJ, **Thomas JP**, Girotti AW. Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism. *Lipids*. 1988 Jun;23(6):580-6.
84. Girotti AW, **Thomas JP**, Jordan JE. Xanthine oxidase-catalyzed crosslinking of cell membrane proteins. *Arch Biochem Biophys*. 1986 Dec;251(2):639-53.
85. **Thomas JP**, Bachowski GJ, Girotti AW. Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins. *Biochim Biophys Acta*. 1986 Dec 10;884(3):448-61.
86. Girotti AW, **Thomas JP**, Jordan JE. Inhibitory effect of zinc(II) on free radical lipid peroxidation in erythrocyte membranes. *J Free Radic Biol Med*. 1985;1(5-6):395-401.
87. Girotti AW, **Thomas JP**, Jordan JE. Prooxidant and antioxidant effects of ascorbate on photosensitized peroxidation of lipids in erythrocyte membranes. *Photochem Photobiol*. 1985 Mar;41(3):267-76.
88. Girotti AW, **Thomas JP**. Superoxide and hydrogen peroxide-dependent lipid peroxidation in intact and triton-dispersed erythrocyte membranes. *Biochem Biophys Res Commun*. 1984 Jan 30;118(2):474-80.
89. Girotti AW, **Thomas JP**. Damaging effects of oxygen radicals on resealed erythrocyte ghosts. *J Biol Chem*. 1984 Feb 10;259(3):1744-52.
90. **Thomas JP**, Kalyanaraman B, Girotti AW. Involvement of preexisting lipid hydroperoxides in Cu(2+)-stimulated oxidation of low-density lipoprotein. *Arch Biochem Biophys*. 1994 Dec;315(2):244-54.
91. Whelan HT, Schmidt MH, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, **Thomas JP**, Meyer GA. The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. *J Neurosurg*. 1993 Oct;79(4):562-8.
92. Lin F, **Thomas JP**, Girotti AW. Hyperexpression of catalase in selenium-deprived murine L1210 cells. *Arch Biochem Biophys*. 1993 Aug 15;305(1):176-85.
93. Struck AT, Hogg N, **Thomas JP**, Kalyanaraman B. Nitric oxide donor compounds inhibit the toxicity of oxidized low-density lipoprotein to endothelial cells. *FEBS Lett*. 1995 Mar 20;361(2-3):291-4.
94. Konorev EA, Struck AT, Baker JE, Ramanujam S, **Thomas JP**, Radi R, Kalyanaraman B. Intracellular catalase inhibition does not predispose rat heart to ischemia-reperfusion and hydrogen peroxide-induced injuries. *Free Radic Res Commun*. 1993;19(6):397-407.
95. **Thomas JP**, Geiger PG, Girotti AW. Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. *J Lipid Res*. 1993 Mar;34(3):479-90.
96. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, **Thomas JP**, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. *Clin Cancer Res*. 2005 Nov 01;11(21):7851-60.
97. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, **Thomas JP**, Fields AL, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. *J Clin Oncol*. 2007 Aug 10;25(23):3456-61.
98. Attia S, Holen KD, **Thomas JP**, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. *Clin Adv Hematol Oncol*. 2008 Jan;6(1):44-54.
99. Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, **Thomas J**, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. *JAMA*. 2008 Jun 04;299(21):2515-23. PMID: PMC3616330
100. Fortune BE, Li X, Kosuri KV, Weatherby LM, **Thomas JP**, Bekaii-Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. *Oncology*. 2009;76(5):333-7.
101. Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, **Thomas JP**, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. *Exp Ther Med*. 2011 Jan;2(1):119-123. PMID: PMC3046871
102. Mulkerin D, LoConte NK, Holen KD, **Thomas JP**, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine.

- Invest New Drugs. 2009 Oct;27(5):461-8. PMID: PMC2899673
103. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, **Thomas J**, Venook AP, Willett C, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. *J Natl Compr Canc Netw*. 2009 Sep;7(8):778-831.
 104. Traynor AM, **Thomas JP**, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. *Invest New Drugs*. 2011 Apr;29(2):316-22. PMID: PMC3038176
 105. Choi BS, Alberti DB, Schelman WR, Kolesar JM, **Thomas JP**, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. *Cancer Chemother Pharmacol*. 2010 Oct;66(5):973-80. PMID: PMC2921466
 106. Saif MW, Oettle H, Vervenne WL, **Thomas JP**, Spitzer G, Visseren-Grul C, Enas N, Richards DA. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. *Cancer J*. 2009;15(4):339-43.
 107. Schelman W, Morgan-Meadows S, Bailey H, Holen K, **Thomas JP**, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2008 Sep;62(4):727-33.
 108. LoConte NK, **Thomas JP**, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2008 Dec;63(1):109-15.
 109. Bailey HH, Alberti DB, **Thomas JP**, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. *Clin Cancer Res*. 2007 Jun 15;13(12):3623-9.
 110. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, **Thomas JP**, Coldwell D. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys*. 2007 May 01;68(1):13-23.
 111. Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, **Thomas JP**. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. *Oncology*. 2005;69(2):130-4.
 112. Dy GK, **Thomas JP**, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. *Clin Cancer Res*. 2005 May 01;11(9):3410-6.
 113. Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, **Thomas JP**. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. *Int J Gastrointest Cancer*. 2002;32(2-3):125-8.
 114. Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, **Thomas JP**, Benson AB 3rd. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. *Oncology*. 2004;66(4):303-9.
 115. Morgan-Meadows S, **Thomas JP**, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of eniluracil, oral 5-fluorouracil and gemcitabine in patients with advanced malignancy. *Invest New Drugs*. 2002 Nov;20(4):377-82.
 116. **Thomas JP**, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H. Phase I clinical and pharmacokinetic trial of iriflufen. *Cancer Chemother Pharmacol*. 2001 Dec;48(6):467-72.
 117. **Thomas JP**, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. *Cancer Chemother Pharmacol*. 2002 Dec;50(6):465-72.
 118. Berlin JD, Catalano P, **Thomas JP**, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. *J Clin Oncol*. 2002 Aug 01;20(15):3270-5.
 119. **Thomas JP**, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. *J Clin Oncol*. 2003 Jan

- 15;21(2):223-31.
120. Carbone PP, Pirsch JD, **Thomas JP**, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. *Cancer Epidemiol Biomarkers Prev.* 2001 Jun;10(6):657-61.
 121. Lubner SJ, Loconte NK, Holen KD, Schelman W, **Thomas JP**, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. *Clin Colorectal Cancer.* 2010 Jul;9(3):157-61. PMID: PMC3058720
 122. Ochoa L, Hurwitz HI, Wilding G, Cohen D, **Thomas JP**, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. *Ann Oncol.* 2000 Oct;11(10):1313-22.
 123. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, **Thomas JP**, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. *J Inorg Biochem.* 2008 Apr;102(4):693-8. PMID: PMC2390869
 124. Liu G, Bailey HH, Arzooonian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, **Thomas JP**. Gemcitabine, Paclitaxel, and piritrexim: a phase I study. *Am J Clin Oncol.* 2003 Jun;26(3):280-4.
 125. Jayakrishnan TT, Groeschl RT, George B, **Thomas JP**, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. *Ann Surg Oncol.* 2014 Jan;21(1):240-7.
 126. Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, **Thomas JP**, Wong YL, Findling JW. Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. *Case Rep Endocrinol.* 2013;2013:675298. PMID: PMC3881387
 127. Christians KK, Tsai S, Mahmoud A, Ritch P, **Thomas JP**, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? *Oncologist.* 2014 Mar;19(3):266-74. PMID: PMC3958454
 128. Jayakrishnan TT, Groeschl RT, George B, **Thomas JP**, Pappas S, Gamblin TC, Turaga KK. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. *Surg Endosc.* 2014 May;28(5):1505-14.
 129. Hwang M, Jayakrishnan TT, Green DE, George B, **Thomas JP**, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. *Eur J Cancer.* 2014 Jul;50(10):1747-1757.
 130. Miura JT, Johnston FM, **Thomas J**, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC. Molecular profiling in gastric cancer: examining potential targets for chemotherapy. *J Surg Oncol.* 2014 Sep;110(3):302-6.
 131. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, **Thomas JP**, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. *HPB (Oxford).* 2015 Feb;17(2):131-9. PMID: PMC4299387
 132. Miura JT, Xiu J, **Thomas J**, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. *Cancer Biol Ther.* 2015;16(5):764-9. PMID: PMC4622996
 133. Miura JT, Johnston FM, Tsai S, George B, **Thomas J**, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol.* 2015 Oct;22(11):3716-23.
 134. Yin N, Qi X, Tsai S, Lu Y, Basir Z, Oshima K, **Thomas JP**, Myers CR, Stoner G, Chen G. p38[?] MAPK is required for inflammation-associated colon tumorigenesis. *Oncogene.* 2016 Feb 25;35(8):1039-48.
 135. **Thomas JP**, Geiger PG. PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue *Cancer Res.* **Thomas JP**, Geiger PG. Abstract 4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue. *Cancer Res.* August 1,.
 136. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, **Thomas JP**, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal

- Liver Metastases: A Meta-Analysis. PLoS One. 2015;10(10):e0139940. PMID: PMC4598149
137. Porter M, Ramaswamy B, Beisler K, Neki P, Single N, **Thomas J**, Hofacker J, Caligiuri M, Carson WE 3rd. A Comprehensive Program for the Enhancement of Accrual to Clinical Trials. *Ann Surg Oncol*. 2016 Jul;23(7):2146-52.
138. Jordan Kharofa, Tracy R. Kelly, Paul S. Ritch, Ben George, Lauren Allison Wiebe, James P. Thomas, Kathleen K. Christians, Douglas B. Evans, Beth Erickson . 5-FU/leucovorin, uifinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. *Journal of Clinical Oncology* . 10.1200/jco.2012.30.15_suppl.e1461 *Journal of Clinical Oncology* 30, no. 15_suppl -published online before print.
139. Kaye AH, Hill JS. Photodynamic therapy. *J Neurosurg*. 1994 Apr;80(4):774-5.

Editorials, Letters To Editor, Other

1. 20080220434 Detection of Molecule Proximity. Patent. 9/11/2008
2. 20080253997 Compositions and Methods for Protecting Cells From Toxic Exposures. Patent. 10/16/2008

Abstracts

1. Fogler WE, Song M, Supko JG, Eder JP, Kufe DW, Tran HT, Madden T, Herbst R, Abbruzzese JL., Tutsch K, **Thomas JP**, Wilding G and Gubish E. Recombinant Human Endostatin Demonstrates Consistent and Predictable Pharmacokinetics Following Intravenous Bolus Administration to Cancer Patients. *Proc Am Soc Clin Oncol*. 20:274. 2001.
2. **Thomas JP**, Schiller JS, Lee F, Perlman S, Winter T, Marnocha R, Arzoomanian R, Alberti D, Volkman J, Tutsch K, Binger K, Feierabend C, Dresen A, Auerbach R and Wilding G. A Phase I and Pharmacokinetic Study of Recombinant Human Endostatin. *Proc Am Soc Clin Oncol* 20:276. 2001.
3. Mundhenke C, **Thomas JP**, Neider R, Sebree LA, Wilding G and Friedl A. Endothelial Cell Kinetics in Skin Wounds and Tumors of Patients Receiving Endostatin. *Proc Am Soc Clin Oncol* 20:277. 2001.
4. Erlichman C, Adjei AA, **Thomas JP**, Wilding G, Reid JM, Sloan JA, Atherton P, Hanson LJ, Alberti D, Kaufmann, and Elliott P. A Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Advanced Cancer. *Proc Am Soc Clin Oncol*. 20:337. 2001.
5. Pipp M, Mulkerin D, Warren D, Hotchkiss W, Berlin J, **Thomas JP**. A Phase II trial of Gemcitabine and 5-Fluorouracil in Advanced Esophageal Cancer. *Proc Am Soc Clin Oncol*. 20:630. 2001.
6. Kolesar J, Berlin JD, Gilchrist KW, Mulkerin D, Bailey HH, **Thomas JP**; Evaluation of NQO1 Gene Expression and Point Mutations in PBMC, Normal Colonic Epithelium and Tumors in Patients Receiving POH. *Proc Am Soc Clin Oncol*. 20:2158. 2001.
7. Wolff RA, Wilding G, Carter S, Abbruzzese JL, **Thomas J**, Bailey H, Mekki Q and Hoff PM, Phase I Study of FK317 in Patients with Refractory Solid Tumors. *Proc Am Soc Clin Oncol*. 20:377. 2001.
8. Berlin JD, Catalano P, **Thomas J**, Kluger J, Haller DG, Benson A. A Phase III study of Gemcitabine in Combination with 5-FU vs. Gemcitabine Alone in Patients with Advanced Pancreatic Carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) Trial. *Proc Am Soc Clin Oncol*. 20:505. 2001.
9. Mulkerin DM, **Thomas JP**, Morgan-Meadows S, Marnocha R, King K, Black S, Lakner M, Fruse M, Volkman J, Wilding G. Phase I Study of Oxaliplatin in Combination with 5-fluorouracil (5FU), leucovorin (LV) and capecitabine (ORAL FOLFOX 6) in patients with advanced or metastatic tumors. *Proc Am Soc Clin Oncol* 22:1310, 2003.
10. **Thomas JP**, Ramanathan RK, Wilding G, Egorin M, H Bailey, Tutsch K, Chatta S, Tutchko K, Renschler M. A Phase I Study of Motexafin Gadolinium (MGD) in Combination with Doxorubicin (DOX). *Proc Am Soc Clin Oncol* 22:909, 2003.
11. Phillip PA, Geyer, SM, Thomas, JP, Pitot, HC, Donehower, R, Kim, GP, Picus, J, Fitch, TR, Mahoney, MR, Erlichman C, Tolerability of OS1-774 (Tarceva) in locally advanced or metastatic hepatocellular (HCC) and biliary (BILI) carcinomas: *Proc Am Soc Clin Oncol* 22: 1461, 2003.
12. **Thomas JP**, Geiger PG. Redox reactions in the uptake and cytotoxicity of motexafin gadolinium. *American Association for Cancer Research Meeting*. 2004.
13. Saltz, LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, **Thomas JP**, Fields ALA, Carver G, Mayer, RJ. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer intergroup trial Cancer and Leukemia Group B (CALGB) C89803. *American Society of Clinical Oncology Meeting*, New Orleans, LO. 2004.
14. Huie M, Greiner L, **Thomas JP**, Mulkerin DL, Smith R, Welsh J, McDermott J, Neider R, Bianco J, Holen KD. Institutional series of selective internal radiation therapy (SIRT) for liver predominant metastatic

- colorectal cancer (MCRC). American Society of Clinical Oncology Meeting, New Orleans, LO. 2004.
15. Wong SJ, Sadasiwan C, Erickson B, Ota D, Mulkerin DL, **Thomas JP**, Holen KD, Meadows S, Telford G, Gore E. A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer. American Society of Clinical Oncology Meeting, New Orleans, LO. 2004.
 16. Philip PA, Mahoney M, **Thomas JP**, Pitot H, Donehower R, Kim G, Picus J, Fitch T, Geyer S, Erlichman C. Phase II Trial of Erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. American Society of Clinical Oncology Meeting, New Orleans, LO. 2004.
 17. **Thomas JP**, Geiger, P, Weichert J. Evaluation of the neovascular toxin AVE8062A by microCT with a novel blood pool contrast agent. American Association for Cancer Research Meeting, Anaheim, 2005.
 18. Hegeman, R.B., Mulkerin, D., Thomas, J.P., Alberti, D., Marnocha, R., Kolesar, J. and Wilding, G. Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors. American Society for Clinical Oncology Meeting. Orlando, FL, 2005.
 19. Richards, D.A., Oettle, H., Vervenne, W.L., Saif, M.W., Thomas, J., Spitzer, G., Enas, N. and Weitzman, A. Randomized double-blind trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas. American Society for Clinical Oncology Meeting. Orlando, FL, 2005.
 20. Schelman, W, Holen, K, Alberti, D, Kolesar, J, Thomas, J. A Phase I Study of Triapine in Combination with irinotecan in Refractory Tumors. American Society for Clinical Oncology Meeting. Atlanta, GA, 2006.
 21. Groteluschen D, Mahoney MR, Pitot HC, Laheru D, Kolesar J, **Thomas JP**, Erlichman C, Holen KD. A Multicenter Phase 2 Consortium (P2C) Study of Triapine in Patients (Pts) with Advanced Adenocarcinoma of the Pancreas. American Society for Clinical Oncology Meeting. Atlanta, GA, 2006.
 22. Fortune B, Kosuri K, Weatherby L, Young D, Xu Y, Muscarella P, Ellison C, **Thomas J**, Bekaii-Saab T. Gemcitabine in combination with oxaliplatin in patients with advanced pancreaticobiliary cancers: The Ohio State University experience. World Gastrointestinal Cancer Symposium. Barcelona, Spain, 2006.
 23. Nag Subir, Kennedy Andrew, Salem Riad, Murthy Ravi, McEwan Alexander, Nutting Charles, Benson Al, Espat Joseph, Ignacia Bilbao, Sharma Ricky, **Thomas James**, Coldwell Douglas. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium (REBOC) (accepted). Chicago, IL 2007.
 24. Choi B, Holen K, Alberti D, Schelman W, Kolesar J, **Thomas J**, Antholine W, Marnocha R, Eickhoff J, Wilding G. A Dose Escalation and Biologic Study of Triapine in Combination with Irinotecan For Patients with Refractory Solid Tumors. American Society for Clinical Oncology Annual Meeting. Chicago, IL 2007.
 25. Kosuri K, Weatherby D, Young D, Bloomston M, Muscarella P, Ellison C, **Thomas J**, Bekaii-Saab TS. A single center retrospective study of gemcitabine and oxaliplatin in patients with advanced pancreas cancer. Gastrointestinal Cancers Symposium. Orlando, FL 2007.
 26. Bekaii-Saab TS, Kosuri K, Campbell J, **Thomas J**, Villalona-Calero M. A phase I dose escalation study of pharmacobiologically based scheduling of capecitabine and mitomycin C (MMC) in patients with gastrointestinal solid malignancies. Gastrointestinal Cancers Symposium. Orlando, FL 2007.
 27. Hill M, Kosuri K, Li X, **Thomas J**, Zalupski M, and Bekaii-Saab T, Poster Presenter. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in patients with metastatic adenocarcinoma of the pancreas (MAP). American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, January 2008.
 28. N. K. LoConte, K.D. Holen, M.R. Mahoney, D. W. Szydlo, J. Picus, W. Maples, H. Pitot, P.A. Philip, J.P. Thomas, C.E. Erlichman. Interim report of a multicenter phase II clinical trial testing a combination of biweekly bevacizumab and daily Erlotinib in patients with metastatic bile tract carcinoma: A Phase II Consortium (P2C) Study. American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, January 2008.
 29. K.D. Holen, M.R. Mahoney, N.K. LoConte, D.W. Szydlo, J. Picus, W.J. Maples, G.P. Kim, H.C., Pitot, P.A. Philip, J.P. Thomas, C.E. Erlichman. Efficacy report of a multicenter phase ii trial testing a biologic-only combination of biweekly bevacizumab and daily Erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) Study. American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, January 2008. Abstract # 4522.
 30. D.M. Dilts, A.B. Sandler, S. Cheng, J. Crites, L. Ferranti, A. Wu, M.A. Bookman, J.P. Thomas, J. Ostroff.

- Accrual to clinical trials at selected comprehensive cancer centers. American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, January 2008. Abstract #6543.
31. B.S. Choi, K.D. Hoen, D. Alberti, W. Schelman, J. Kolesar, J.P. Thomas, W. Antholine, R. Marnocha, J. The maximum tolerated dose and biologic effects of 3-amino-pyridine-2-carboxaldehyde thiosemicarbazone (T) in combination with Irinotecan (I) for patients with refractory solid tumors. American Society for Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, January 2008. Abstract #2527.
 32. CR Balint, KA Blum, W Blum, JC Byrd, WE Carson, KK Chan, C-S Chen, D Cohn, B Fischer, AJ Johnson, C Kefauver, MV Knopp, GB Lesinski, DM Lucas, D O'Malley, G Marcucci, GA Otterson, MA Phelps, B Ravaswamy, LJ Schaaf, MH Shah, C Shapiro, J Thomas, MA Villalona-Calero, and D Wilkins. Phase I Trials of Ant-Cancer Agents: The Ohio State University National Cancer Institute (NCI) U01 CA 076576 MR Grever, MD, Principal Investigator. 2008 National Cancer Institute (NCI) Translational Meeting Washington, D.C.
 33. Martin LK, Li X, Kim SE, Balint C, Kosuri K, **Thomas JP**, Zalupski M, Bekaii-Saab, TS. A Multicenter Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, AACR 2009 Meeting Denver, CO 4/2009.
 34. T. Bekaii-Saab, A. Majumber. E. Trolli, J. Thomas. Exploring the role of CA 19-9 level as predictor of survival in patients with advanced pancreatic adenocarcinomas. The Joint ECCO 15 and 34th ESMO Multidisciplinary Congress Meeting Berlin, Germany September 2009.
 35. Tanios Bekaii-Saab, Mitch Phelps, Xiaobai Li, Motoyasu Saji, Kavitha Kosuri, Laura Goff, John Kauh, Bert O'Neil, Christopher South, **James Thomas**, Stephanie Balsom, Nicole Chattah, Catherine Balint, Ryan Liersemann, Vasily Vasko, William Marsh, L. Austin Doyle, Matthew Ringel, Miguel A. Villalona. A Multi-institutional Study of AZD6244 in Patients with Advanced Biliary Cancers. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009.
 36. L. Katherine Martin, Xiaobai Li, Sharon E. Kim, Catherine R. Balint, Kavitha V. Kosuri, James P. Thomas, Mark M. Zalupski, Tanios Bekaii-Saab. A multi-center phase II study of the combination of bevacizumab, fixed dose rate gemcitabine, and infusional 5-fluorouracil in patients with advanced pancreas cancer. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009 (late breaking abstract).
 37. CR Balint, KA Blum, W Blum, JC Byrd, WE Carson, KK Chan, C-S Chen, D Cohn, B Fischer, AJ Johnson, C Kefauver, MV Knopp, GB Lesinski, DM Lucas, D O'Malley, G Marcucci, GA Otterson, MA Phelps, B Ravaswamy, LJ Schaaf, MH Shah, C Shapiro, J Thomas, MA Villalona-Calero, and D Wilkins. Phase I Trials of Ant-Cancer Agents: The Ohio State University National Cancer Institute (NCI) U01 CA 076576 MR Grever, MD, Principal Investigator. 2009 National Cancer Institute (NCI) Translational Meeting Vienna, VA.
 38. M.B. Lustberg, J. Nuovo, J.P. Thomas, P.J. Monk, S. Kim, M. Villalona-Calero, T. Bekaii-Saab. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: a dose-escalating phase I study. American Society for Clinical Oncology 2009 Annual Meeting Orlando, FL 5/2009.
 39. Hwang, M., Jayakrishana, T.T., Green, B. George, B., Thomas, J.P., Pappas, S.G., Gampblin, T.C. and Turaga, K.T. Systematic Review of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases in the Setting of Extrahepatic Disease for Surgical Oncology Annual Meeting, 2013.